Cancer Biomarkers - Volume 27, issue 1

Authors: Li, Xiaoting | Liu, Kun | Zhou, Wei | Jiang, Zhe

Article Type: Research Article

Abstract: This article has been retracted, and the online PDF replaced with this retraction notice.

Keywords: Oral cancer, DDP, resistance, miR-155, FoxO3a

DOI: 10.3233/CBM-190555

Citation: Cancer Biomarkers, vol. 27, no. 1, pp. 105-111, 2020

Authors: Liu, Wenqi | Liu, Jing | Zhang, Qiangqiang | Wei, Li

Article Type: Research Article

Abstract: BACKGROUND: Increasing evidence have shown that miRNAs play an important role in the development and progression of non-small cell lung cancer (NSCLC). OBJECTIVE: In this study, we aimed to analyze serum exosomal miR-216b expression in NSCLC patients and its potential clinical significance. METHODS: A total of 105 NSCLC patients and 60 healthy controls were enrolled, and quantitative reverse transcription polymerase chain reaction (qRT-PCR) was performed to detect serum exosomal miR-216b expression. RESULTS: The results demonstrated that serum exosomal miR-216b levels were significantly lower in NSCLC patients compared to controls. In …addition, receiver operating characteristic analysis revealed that serum exosomal miR-216b had better diagnostic accuracy than CEA, CYFRA21-1 or SCCA. Moreover, serum exosomal miR-216b levels in early-stage NSCLC patients were dramatically increased after surgical resection, and patients with low serum exosomal miR-216b expression had higher lymph node metastasis probability. Furthermore, low serum exosomal miR-216b expression was closely associated with poor prognosis. Finally, multivariate analysis showed that serum exosomal miR-216b could serve as an independent predictor of NSCLC. CONCLUSIONS: Collectively, serum exosomal miR-216b might be used as a potential diagnostic and prognostic biomarker for NSCLC. Show more

Keywords: non-small cell lung cancer, exosomes, miR-216b, prognosis

DOI: 10.3233/CBM-190914

Citation: Cancer Biomarkers, vol. 27, no. 1, pp. 113-120, 2020

Authors: Yamada, Keita | Higashi, Kiyoshi | Nagahori, Hirohisa | Saito, Koichi

Article Type: Research Article

Abstract: BACKGROUND: Pancreatic ductal adenocarcinoma is a devastating malignancy with an extremely poor prognosis. Although the most widely used biomarker for pancreatic cancer is carbohydrate antigen CA19-9, it is elevated mainly in the late stage of pancreatic cancer. Some serum natural antibodies against carbohydrates have been shown to be possible diagnostic markers for cancer. OBJECTIVE: This study was conducted to determine whether the level of natural antibodies against carbohydrates fluctuates in pancreatic ductal adenocarcinoma. METHODS: Serum from pancreatic cancer subjects (n = 55) and 43 subjects free of malignant …disease were studied. The contents of natural antibodies against sialyl glycans and CA19-9 in serum were determined by enzyme-linked immunosorbent assay. RESULTS: The level of serum anti-3’-sialyllactose antibodies in pancreatic cancer subjects was significantly lower than that in healthy controls. In contrast, the amounts of serum antibodies against other sialyl glycans were comparable between the two groups. Concentration of serum anti-3’-sialyllactose IgG provided excellent AUC of 0.86, with sensitivity 82%, specificity 81%, and accuracy 82%. The combination of serum anti-3’-sialyllactose IgG with CA19-9 improved the sensitivity of pancreatic cancer detection at an early stage. CONCLUSIONS: Natural antibodies against 3’-sialyllactose constitute a promising biomarker for pancreatic cancer detection. The measurement of serum anti-3’-sialyllactose antibodies could play a supportive role in diagnostics and complement the performance of CA19-9 for the early detection of pancreatic ductal adenocarcinoma. Show more

Keywords: Pancreatic ductal adenocarcinoma, natural antibody, 3’-sialyllactose, CA19-9

DOI: 10.3233/CBM-190158

Citation: Cancer Biomarkers, vol. 27, no. 1, pp. 121-128, 2020

Authors: Saman, S. | Stagno, M.J. | Warmann, S.W. | Malek, N.P. | Plentz, R.R. | Schmid, E.

Article Type: Research Article

Abstract: OBJECTIVE: The EDIM (Epitope detection in monocytes) blood test is based on two biomarkers Apo10 and TKTL1. Apo10 is responsible for cell proliferation and resistance to apoptosis. TKTL1 plays a major role in anaerobic glycolysis of tumor cells, leading to destruction of the basal membrane and metastasis as well as in controlling cell cycle. For the first time we analyzed Apo10 and TKLT1 in patients with cholangiocellular (CCC), pancreatic (PC), and colorectal carcinoma (CRC). METHODS: Blood samples of 62 patients with CCC, PC, and CRC were measured and compared to 29 control patients. We also investigated …13 patients with inflammatory conditions, because elevated TKTL1 and Apo10 have been previously described in affected individuals. Flow cytometry was used to detect surface antigens CD14 + /CD16 + (activated monocytes/macrophages). Percentages of macrophages harboring TKTL1 and Apo10 were determined. A combined EDIM score (EDIM-CS: TKTL1 plus Apo10) was calculated. Results were correlated with serum tumor markers CEA and CA19-9. RESULTS: Patients with CCC had 100% positive EDIM-CS but CEA and CA19-9 were positive in only 22.2% and 70%, respectively. Patients with PC had 100% positive EDIM-CS but positive tumor markers in only 37.5% (CEA) and 72.7% (CA19-9). Patients with CRC had 100% positive EDIM-CS but only 50% positive CEA. EDIM-CS was positive in 100% (62/62) of all cancer patients and in 0% of healthy individuals. Of the individuals with inflammation, 7.7% had a positive EDIM-CS. CONCLUSION: The sensitivity of the EDIM blood test and the comparison with traditional tumor markers indicate that this new test might improve the detection of carcinomas (CCC, PC and, CRC) and might be relevant for the diagnosis of all tumor entities. Show more

Keywords: Biomarker, Apo10, TKTL1, EDIM blood test, PanTum detect, biologic biopsy, pancreas cancer, cholangiocellular carcinoma, colorectal carcinoma

DOI: 10.3233/CBM-190414

Citation: Cancer Biomarkers, vol. 27, no. 1, pp. 129-137, 2020